U.S. markets close in 6 minutes

ContraFect Corporation (CFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.1150-0.0050 (-0.12%)
As of 3:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close4.1200
Open4.1500
Bid4.0900 x 1300
Ask4.1000 x 1800
Day's Range4.0400 - 4.2100
52 Week Range3.4400 - 7.6300
Volume87,536
Avg. Volume348,906
Market Cap161.854M
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-0.9850
Earnings DateAug 12, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Were Hedge Funds Right About ContraFect Corp (CFRX)?
    Insider Monkey

    Were Hedge Funds Right About ContraFect Corp (CFRX)?

    In this article we will analyze whether ContraFect Corp (NASDAQ:CFRX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into […]

  • CFRX: Presentations at ECCMID Highlight Advances in Lysin Platform…
    Zacks Small Cap Research

    CFRX: Presentations at ECCMID Highlight Advances in Lysin Platform…

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Presentations at ECCMID Highlight New Data for DLA Agents On July 19, 2021, ContraFect (NASDAQ:CFRX) announced multiple data presentations at the 31 st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). A copy of the presentations can be accessed on the company’s website here . An

  • ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
    GlobeNewswire

    ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID

    YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced multiple presentations, including two oral presentations, of data from its portfolio of DLAs from the 31st European Congress of Clinical Microbi